Clinical trial
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil)…
NCT00114816 · Finnish Breast Cancer Group, Other · Completed
Key facts
| NCT number | NCT00114816 |
|---|---|
| Title | Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer |
| Official title | A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer |
| Lead sponsor | Finnish Breast Cancer Group, Other |
| Collaborators | Hoffmann-La Roche Industry Sanofi AstraZeneca |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, docetaxel |
| Enrollment | 1,500 |
| Start date | Jan 1, 2004 |
| Completion | Apr 1, 2007 |
| First posted | Jun 20, 2005 |
| Last update posted | May 21, 2007 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: